|
|
Blood, 1 September 2006, Vol. 108, No. 5, pp. 1684-1689.
Prepublished online as a Blood First Edition Paper on May 11, 2006; DOI 10.1182/blood-2005-11-011486.
Previous Article | Next Article 
Submitted November 22, 2005
Accepted April 24, 2006
Interstitial uniparental isodisomy at clustered breakpoint
intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies
Karen Stephens*, Molly Weaver, Kathleen A Leppig, Kyoko Maruyama, Peter D Emanuel, Michelle M Le Beau, and Kevin M Shannon
Departments of Medicine, Laboratory Medicine, University of Washington, Seattle, WA, USA
Departments of Medicine, University of Washington, Seattle, WA, USA
Department of Pediatrics, University of Washington, Seattle, WA, USA
Division of Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, USA
Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA
Department of Pediatrics and Comprehensive Cancer Center, University of California, San Francisco,CA
* Corresponding author; email: millie{at}u.washington.edu.
To identify the mechanism of loss of heterozygosity
(LOH) and potential modifier gene(s), we investigated
the molecular basis of somatic NF1 inactivation in
myeloid malignancies from ten children with
neurofibromatosis type 1. Loci across a minimal 50 Mb
region of primarily the long arm of chromosome 17 showed
LOH in 8 cases, whereas a <9 Mb region of loci flanking
NF1 had LOH in the remaining 2 cases. Two complementary
techniques, quantitative PCR and fluorescence in situ
hybridization (FISH), were employed to determine if the
copy number at loci that showed LOH was one or two
(i.e., deleted or isodisomic). The 2 cases with LOH
limited to <9 Mb were intrachromosomal deletions. Among
the 8 leukemias with 50 Mb LOH segments, four had
partial uniparental isodisomy and four had interstitial
uniparental isodisomy. These isodisomic cases showed
clustering of the centromeric and telomeric LOH
breakpoints. This suggests that the cases with
interstitial uniparental isodisomy arose in a leukemia-
initiating cell by double homologous recombination
events at intervals of preferred mitotic recombination.
Homozygous inactivation of NF1 favored outgrowth of the
leukemia-initiating cell. Our studies demonstrate that
LOH analyses of loci distributed along the chromosomal
length along with copy-number analysis can reveal novel
mechanisms of LOH that may potentially identify regions
harboring " cryptic" tumor suppressor or
modifier genes
whose inactivation contribute to tumorigenesis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, N. L. Harris, M. M. Le Beau, E. Hellstrom-Lindberg, A. Tefferi, et al.
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
Blood,
July 30, 2009;
114(5):
937 - 951.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Lange
A FISH 'n chips appetizer
Blood,
January 15, 2008;
111(2):
480 - 481.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Flotho, C. P. Kratz, and C. M. Niemeyer
How a rare pediatric neoplasia can give important insights into biological concepts: a perspective on juvenile myelomonocytic leukemia
Haematologica,
November 1, 2007;
92(11):
1441 - 1446.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Mohamedali, J. Gaken, N. A. Twine, W. Ingram, N. Westwood, N. C. Lea, J. Hayden, N. Donaldson, C. Aul, N. Gattermann, et al.
Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes
Blood,
November 1, 2007;
110(9):
3365 - 3373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Suela, C. Largo, B. Ferreira, S. Alvarez, M. Robledo, A. Gonzalez-Neira, M. J. Calasanz, and J. C. Cigudosa
Neurofibromatosis 1, and Not TP53, Seems to Be the Main Target of Chromosome 17 Deletions in De Novo Acute Myeloid Leukemia
J. Clin. Oncol.,
March 20, 2007;
25(9):
1151 - 1152.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. G. Rucker, L. Bullinger, K. Dohner, and H. Dohner
In Reply
J. Clin. Oncol.,
March 20, 2007;
25(9):
1152 - 1153.
[Full Text]
[PDF]
|
 |
|
|
|